NeuBase Therapeutics Inc NBSE:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/02/21 EST
9.27quote price arrow down-0.66 (-6.65%)
Volume
110,718
52 week range
4.52 - 12.89

...

Loading . . .

KEY STATS

  • Open9.85
  • Day High9.93
  • Day Low9.23
  • Prev Close9.27
  • 52 Week High12.89
  • 52 Week High Date02/10/21
  • 52 Week Low4.52
  • 52 Week Low Date03/23/20
  • Market Cap214.88M
  • Shares Out23.18M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta0.13
  • 1 Year % Change24.6

RATIOS/PROFITABILITY

  • EPS (TTM)-0.81
  • P/E (TTM)-11.39
  • Fwd P/E (NTM)-10.02
  • EBITDA (MRQ)-17.747M
  • ROE (MRQ)-95.35%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/12/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest NeuBase Therapeutics Inc News

There is no recent news for this security.

Latest NBSE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to...
Dietrich Stephan
President
William Mann Ph.D.
Chief Operating Officer
Sam Backenroth
Chief Financial Officer
Address
700 Technology Dr
Pittsburgh, PA
15219-3124
United States